Rani Therapeutics Holdings, Inc. (RANI) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 0.82 |
| Open | 0.82 |
| Day High | 0.83 |
| Day Low | 0.77 |
| 52-Week High | 3.87 |
| 52-Week Low | 0.44 |
| Volume | 436,513 |
| Average Volume | 973,058 |
| Market Cap | 50.56M |
| PE | -1.89 |
| EPS | -0.41 |
| Moving Average 50 Days | 0.81 |
| Moving Average 200 Days | 1.21 |
| Change | -0.05 |
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer
GlobeNewswire Inc.
Jan 28, 2026 12:00 PM GMT
SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the p
Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen
GlobeNewswire Inc.
Jan 08, 2026 12:00 PM GMT
- A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight loss of GLP-1/GLP-2 dual agonist, PG-102, administered orally via RaniPill® capsule versus subcutaneous injection - SAN JOSE, Calif., Jan. 08, 2026 (
Rani Therapeutics to Participate in the Evercore Healthcare Conference
GlobeNewswire Inc.
Nov 24, 2025 9:05 PM GMT
SAN JOSE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that